Journals / Medicine Science / 2018 / Cilt: 7 - Sayı: 4

Prevalence of MMP-3 E45K polymorphism in Turkish patients with endometrial carcinoma

Pages
762–765
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Besides no significant correlation was found between MMP-3 E45K polymorphisms and clinical characteristics, such as histology, grade, metastasis and family history. ur study suggests that the MMP-3 E45K polymorphism is not associated with endometrial carcinoma process in Turkish patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Endometrial carcinoma is a metastatic and recurrent disease has a worse prognosis.
📊
Key Findings & Data:We aim to investigate the MMP-3 gene polymorphism in Turkish patients with endometrial carcinoma.
💡
Conclusion & Impact:Besides no significant correlation was found between MMP-3 E45K polymorphisms and clinical characteristics, such as histology, grade, metastasis and family history. ur study suggests that the MMP-3 E45K polymorphism is not associated with endometrial carcinoma process in Turkish patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Endometrial carcinoma is a metastatic and recurrent disease has a worse prognosis. We aim to investigate the MMP-3 gene polymorphism in Turkish patients with endometrial carcinoma. In recent years, number of genetic studies have been increased to find new prognostic and theraupeutic markers. Matrix metalloproteinases [MMPs] are proteolytic enzymes that degrade all components of the extracellular matrix which are play an important role of cancer metastasis and invasion. MMP-3, also known as stromelysin-1, to lyse basal membrane collagen and induce the synthesis of some other MMPs. 97 patients with endometrial carcinoma and 100 healthy controls were included in this study. MMP-3 E45K polymorphism was determined using polymerase chain reaction/ restriction fragment length polymorphism in study groups. There were no significant differences between any genotypes or allele in control and patient groups for MMP-3 E45K polymorphism. Besides no significant correlation was found between MMP-3 E45K polymorphisms and clinical characteristics, such as histology, grade, metastasis and family history. ur study suggests that the MMP-3 E45K polymorphism is not associated with endometrial carcinoma process in Turkish patients.

🔖

Cite This Article

KURAN, S. B., KARAGEDİK, E. H., İYİBOZKURT, C., İPLİK, E. S., ÇAKMAKOĞLU, B., ERGEN, A. (2018). Prevalence of MMP-3 E45K polymorphism in Turkish patients with endometrial carcinoma. Medicine Science, Cilt: 7 - Sayı: 4, 762–765. https://ajindex.com/articles/277278

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Colombo N, Preti E, Landoni F, et al. ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:35-9.
  2. Nicholson MR, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Modern Pathol. 2009;19:1091-100.
  3. Noguera R, Nieto OA, Tadeo I, et al. Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histol Histopathol. 2012;27:693-705.
  4. Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: A dynamic view. Dev Biol. 2010;341:126-40.
  5. Catalano V, Turdo A, Di F, et al. Tumor and its microenvironment: A synergistic interplay. Semin Cancer Biol. 2013;23:522-32.
  6. Lu P, Weaver VM, Werb ZJ. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 2012;20:395-406.
  7. Deryugina E, Quigley J. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta. 2010;1803:103-20.
  8. Butler GS, Overall CM. Updated biological roles for matrix metalloproteinases and new “intracellular” substrates revealed by degradomics. Biochemistry. 2009;48:10830-45.
  9. Honkavuori M, Talvensaari-Mattila A, Soini Y,et al. 2007. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol. 104:217-21.
  10. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000;6:4823-30.
  11. Bodey B, Bodey B Jr, Siegel SE, et al. Matrix metalloproteinase expression in childhood astrocytomas. Anticancer Res. 2000;20:3287-92.
  12. Mercapide J, Lopez De Cicco R, Castresana JS, et al. Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. Int J Cancer. 2003;106:676–82.
  13. Blons H, Gad S, Zinzindohoue F, et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2004;10:25949. Szyllo K, Smolarz B, Romanowicz-Makowska H, et al. The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer. J Exp Clin Cancer Res. 2002;21:357-61. Raleigh SM, van der Merwe L, Ribbans WJ, et al. Variants within the MMP3 gene are associated with Achilles tendin